Bone Health Experts Issue Osteoporosis Treatment Guidance During COVID-19

August 10, 2020

As the COVID-19 pandemic became more serious, the Endocrine Society joined a coalition of bone health organizations that united to issue new osteoporosis treatment guidelines. Aside from addressing the challenges social distancing has placed on treating these patients, the coalition has also focused on the administration of osteoporosis medications including denosumab, teriparatide, abaloparatide, romosozumab, and […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Bone and Mineral COVID-19

←All in the Timing: Osteoporosis Medications

Asked & Answered: The Virtual Reality of CEU & EBR 2020→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today